89581-58-8

Usage

Uses

Used in Plastics and Rubber Industry:
BUTTPARK 153\57-36 is used as an antioxidant and stabilizer for plastics and rubber, protecting them from degradation caused by heat, light, or oxygen exposure. This helps maintain the quality and performance of the materials, extending their shelf life.
Used in Adhesives Production:
In the adhesives industry, BUTTPARK 153\57-36 is used as a stabilizer to prevent the degradation of adhesives, ensuring their long-term stability and performance.
Used in Food Packaging:
BUTTPARK 153\57-36 is used as an antioxidant in food packaging to protect the packaging material from degradation, ensuring the freshness and quality of the packaged food products.
Used in Lubricants and Fuels Production:
BUTTPARK 153\57-36 is used as a stabilizer in the production of lubricants and fuels, preventing their degradation and maintaining their performance and quality over time.

InChI:InChI=1/C6H5ClN2O2/c1-3-2-4(5(10)11)9-6(7)8-3/h2H,1H3,(H,10,11)

Upstream product

• 89793-11-3 methyl 2-chloro-6-methylpyrimidine-4-carboxylate 
• 265328-14-1 ethyl 2-chloro-4-methylpyrimidine-6-carboxylate 

Downstream Products

• 16858-56-3 2-chloro-6-methylpyrimidine-4-carbonitrile 
• 1150645-44-5 2-chloro-4-{3-[4-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-3,5-dimethyl-phenyl]-[1,2,4]oxadiazol-5-yl}-6-methyl-pyrimidine 
• 306960-81-6 2-chloro-4-methylpyrimidine-6-carbonyl chloride 

Relevant academic research and scientific papers

SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA

Disclosed are compounds that are chemical inhibitors of SOX11. The compounds disclosed are useful in treatment of various cancers.

NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES

The invention relates to novel pyrimidine-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

NOVEL PYRIMIDINE DERIVATIVES

The invention relates to novel pyrimidine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII) or Formula (IX)

NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES

The invention relates to novel pyrimidine-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula I.

IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES

The invention relates to new bicyclic heterocyclic derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS

The present invention relates to compounds and methods useful as inhibitors of nitric oxide synthase. Certain compounds of the subject invention have the following structural formula: wherein T, X, and Y are independently selected from the group consisting of CR4, N, NR4, S, and O; U is selected from the group consisting of CR10 and N; V is selected from the group consisting of CR4 and N; W and W' are independently selected from the group consisting of CH2, CR7R8, NR9, O, N(O), S(O)q and C(O); n, m and p are independently an integer from 0 to 5; q is 0, 1, or 2; and other substituents are as defined herein. Other compounds of the subject invention have structural formulas as defined herein. Also disclosed herein are pharmaceutical compositions comprising the compounds of the subject invention

Inhibitors of NF-kappaB and AP-1 gene expression: SAR studies on the pyrimidine portion of 2-chloro-4-trifluoromethylpyrimidine-5-[N-(3', 5'-bis(trifluoromethyl)phenyl)carboxamide].

We investigated the structure-activity relationship studies of N-[3, 5-bis(trifluoromethyl)phenyl][2-chloro-4-(trifluoromethyl)pyrimidin-5 -yl]carboxamide (1), an inhibitor of transcription mediated by both NF-kappaB and AP-1 transcription factors, with the goal of improving its potential oral bioavailability. Compounds were examined for cell-based activity, were fit to Lipinski's rule of 5, and were examined for potential gastrointestinal permeability using the intestinal epithelial cell line, Caco-2. Selected groups were substituted at the 2-, 4-, and 5-positions of the pyrimidine ring using solution-phase combinatorial methodology. The introduction of a fluorine in the place of 2-chlorine of 1 resulted in a compound with comparable activity. However, other substitutions at the 2-position resulted in a loss of activity. The trifluoromethyl group at the 4-position could be replaced with a methyl, ethyl, chlorine, or phenyl without a substantial loss of activity. The carboxamide group at the 5-position is critical for activity. If it was moved to the 6-position, the activity was lost. The 2-methyl analogue of 1 (81) showed comparable in vitro activity and improved Caco-2 permeability compared to 1.